Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 12 Oct 2006 The expected completion date for this trial is now 1 Dec 2007.
- 15 Oct 2005 New trial record.